Compounds that inhibit MCL-1 protein

Patent metadata

Field	Value
Publication number	US-9562061-B2
Application number	US-201514839149-A
Country	US
Kind code	B2
Filing date	Aug 28, 2015
Priority date	Aug 29, 2014
Publication date	Feb 7, 2017
Grant date	Feb 7, 2017

Abstract

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

First claim

What is claimed is:

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

2. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

3. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

4. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

5. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

6. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

7. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

8. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

9. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

10. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutically acceptable salt of the compound according to claim 1 .

12. A pharmaceutically acceptable salt of the compound according to claim 2 .

13. A pharmaceutically acceptable salt of the compound according to claim 3 .

14. A pharmaceutically acceptable salt of the compound according to claim 4 .

15. A pharmaceutically acceptable salt of the compound according to claim 5 .

16. A pharmaceutically acceptable salt of the compound according to claim 6 .

17. A pharmaceutically acceptable salt of the compound according to claim 7 .

18. A pharmaceutically acceptable salt of the compound according to claim 8 .

19. A pharmaceutically acceptable salt of the compound according to claim 9 .

20. A pharmaceutically acceptable salt of the compound according to claim 10 .

21. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising the compound according to claim 4 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition comprising the compound according to claim 5 and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising the compound according to claim 6 and a pharmaceutically acceptable carrier.

27. A pharmaceutical composition comprising the compound according to claim 7 and a pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising the compound according to claim 8 and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable carrier.

30. A pharmaceutical composition comprising the compound according to claim 10 and a pharmaceutically acceptable carrier.

Assignees

• Amgen Inc

Inventors

• Brown Sean P
• Li Yunxiao
• Taygerly Joshua
• Vimolratana Marc
• Wang Xianghong
• Zancanella Manuel

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07D513/10 Primary

  Spiro-condensed systems · CPC title

• C07D513/08 Primary

  Bridged systems · CPC title

• C07D498/00

  Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (4-oxa-1-azabicyclo [3.2.0] heptanes, e.g. oxapenicillins C07D503/00; 5-oxa-1-azabicyclo [4.2.0] octanes, e.g. oxacephalosporins C07D505/00; analogues thereof having ring oxygen atoms in other position C07D507/00) · CPC title